在2019年冠状病毒病患者中从呼吸系统衰竭中恢复
Miraç Öz1, Serhat Erol1, Aslıhan Gürün Kaya1
1Department of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Turkey.
Thoracic research and practice
|November 28, 2023
概括
大多数需要长期氧气治疗 (LTOT) 的COVID-19患者在3个月内得到改善. 较低的氧和度 (SaO2) 和下网膜预测COVID-19肺炎后长时间的LTOT需求.
科学领域:
- 肺部医学 肺部医学
- 传染性疾病 传染性疾病
- 关键的护理关键的护理
背景情况:
- 冠状病毒疾病2019 (COVID-19) 可能导致低血氧呼吸衰竭.
- 对于COVID-19患者所需的长期氧气治疗 (LTOT) 持续时间尚未确定.
研究的目的:
- 确定COVID-19肺炎患者长期氧气治疗 (LTOT) 需求的预测因素.
- 为了区分需要LTOT不到3个月的患者和需要3个月或更长时间的患者.
主要方法:
- 对70名需要LTOT的住院COVID-19患者进行前性单中心研究.
- 患者被分为两组:LTOT<3个月 (I组) 和LTOT≥3个月 (II组).
- 多变量逻辑回归分析了包括SaO2,PaO2和成像结果在内的因素.
主要成果:
- 虽然这两组都显示了PaO2的改善,但在I组中,这种增加明显更大.
- 较低的基线氧和度 (SaO2) 和下网膜的存在是长期LTOT (≥3个月) 的显著预测因素.
- 几率比率表明SaO2 (0.853) 和亚多网络 (0.171) 是关键因素.
结论:
- 大多数COVID-19患者的呼吸衰竭可能会在3个月内恢复.
- 图像成像中的SaO2水平和脑下网膜是预测需要延长LTOT超过3个月的关键指标.
更多相关视频
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
2.8K
09:54Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
1.8K
相关概念视频
Acute Respiratory Failure-V
142
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
142
Acute Respiratory Failure-II
241
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
241
Acute Respiratory Failure-III
187
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
187
Acute Respiratory Failure-I
213
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
213
Acute Respiratory Failure-IV
159
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
159
Pneumonia IV: Management
333
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
333
